Summary
Unable to verify key claims (e.g., patent expiration, generics/competition/prices, formulations, regulatory approvals geography, study focus, and incidence of specific adverse events like anaphylaxis/angioedema) against the provided FDA label excerpt because the supplied prescribing information does not contain those details; several safety/statements are only partially supported by the excerpt.
Category Scores
Accurate Statements
Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis.
Section 1.1 indicates DUPIXENT is indicated for moderate-to-severe atopic dermatitis (AD); label excerpt does not use term "biologic" but supports the indication.
Dupixent (dupilumab) is a biologic medication used to treat asthma.
Section 1.2 indicates DUPIXENT as add-on maintenance treatment for moderate-to-severe asthma; label excerpt does not explicitly say "biologic".
Dupixent (dupilumab) is a biologic medication used to treat chronic rhinosinusitis with nasal polyposis.
Section 1.3 indicates DUPIXENT as add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP); label excerpt does not explicitly say "biologic".
In 2020, the FDA approved Dupixent for the treatment of prurigo nodularis.
Section 1.5 indicates DUPIXENT is indicated for prurigo nodularis (PN); the provided excerpt does not include the year 2020.
Unsupported Statements
Dupixent's patent protection is set to expire in 2028 for the treatment of atopic dermatitis.
Not supported by the provided prescribing information excerpt.
Dupixent's patent protection is set to expire in 2030 for the treatment of asthma.
Not supported by the provided prescribing information excerpt.
The patent expiration will allow generic versions of Dupixent to enter the market.
Not supported by the provided prescribing information excerpt.
Generic versions of Dupixent may lead to increased competition.
Not supported by the provided prescribing information excerpt.
Generic versions of Dupixent may lead to potentially lower prices.
Not supported by the provided prescribing information excerpt.
The patent expiration of Dupixent could be beneficial for patients by making the medication more affordable and accessible.
Not supported by the provided prescribing information excerpt.
The article claims that generic versions of Dupixent may be available in different formulations, such as oral or topical forms.
Not supported by the provided prescribing information excerpt.
Sanofi and Regeneron are studying Dupixent in eosinophilic esophagitis.
The provided excerpt includes an indication for eosinophilic esophagitis but does not support that this is a current 'studying' activity by specific companies.
Sanofi and Regeneron are studying Dupixent in chronic obstructive pulmonary disease (COPD).
The provided excerpt includes an indication for COPD but does not support that this is a current 'studying' activity by specific companies.
Dupixent has received regulatory approvals in the United States, Europe, and Japan.
The provided prescribing information excerpt does not state geography of approvals.
Dupixent has regulatory approval for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Supported as indications in Section 1.1-1.3, but the excerpt does not establish 'regulatory approval' in the sense of agency scope beyond the label itself; geography not supported.
Regulatory approvals of Dupixent were based on the results of clinical trials demonstrating efficacy and safety.
Not explicitly stated in the provided excerpt.
Clinical trials have demonstrated the efficacy and safety of Dupixent for treating various inflammatory and allergic conditions.
The excerpt contains efficacy study descriptions but does not support a broad claim covering 'various' conditions and 'safety' as a generalized statement.
Dupixent has been shown in patients with asthma and chronic rhinosinusitis with nasal polyposis to reduce symptoms.
The excerpt describes efficacy endpoints (e.g., asthma exacerbation reduction; NPS score improvement) but does not directly support the phrasing 'reduce symptoms' for both conditions.
Dupixent has been shown in patients with asthma and chronic rhinosinusitis with nasal polyposis to improve quality of life.
No quality-of-life statement is included in the provided excerpts for asthma or CRSwNP.
Dupixent has been shown to increase lung function in patients with asthma.
The provided excerpt does not include lung function increases.
The most common side effects of Dupixent include injection site reactions.
The provided excerpt does not list or support 'most common' adverse reactions as injection site reactions.
The most common side effects of Dupixent include conjunctivitis.
The excerpt notes conjunctivitis and keratitis under clinically significant adverse reactions elsewhere in labeling, but it does not support 'most common' ranking.
The most common side effects of Dupixent include eye inflammation.
The excerpt supports conjunctivitis and keratitis as adverse reactions but does not support 'most common' or the generalized phrase 'eye inflammation' as 'most common'.
More serious side effects of Dupixent, such as anaphylaxis, have been reported.
The excerpt supports hypersensitivity reactions including anaphylaxis, but it does not support that anaphylaxis is a 'more serious side effect' category and does not provide frequency or ranking.
More serious side effects of Dupixent, such as angioedema, have been reported.
The excerpt supports hypersensitivity including angioedema, but it does not support that angioedema is a 'more serious side effect' category and does not provide frequency or ranking.
Contradictions
Important Omissions
For claims about adverse effects being 'most common,' the labeling excerpt provided does not include incidence/frequency data to substantiate 'most common' wording.
Importance:
Moderate
For multiple non-label claims (patent expiration/generics/prices/formulations/regional approvals/company 'studying'), the FDA label excerpt contains no such details; a robust evaluation would require label sections or other authoritative sources not provided here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Safety-related statements (anaphylaxis, angioedema, conjunctivitis/keratitis) are generally consistent with the excerpted warnings/adverse reactions, but several statements use frequency/ranking ('most common'/'more serious') that are not supported by the provided text, limiting precision rather than showing direct label conflicts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Many claims are outside the scope of the provided FDA label excerpt (patents/generics/pricing/formulations/regions and company studies). Several safety claims include unsupported frequency/ranking wording ('most common').
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpt (Sections 1.1-1.6 for indications; Sections 5.1 and 6.1 for hypersensitivity and eye-related adverse reactions), and remove or qualify statements about patents, generics, approvals in specific regions, and 'most common' adverse events unless the label excerpt provides incidence/frequency data.